FDA Approves Lower Dose of Cabazitaxel for Prostate Cancer

U.S. Food and Drug Administration


On September 14, 2017, the U.S. Food and Drug Administration (FDA) approved a lower dose of cabazitaxel (20 mg/m2 every 3 weeks) (Jevtana®, Sanofi-Aventis) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.  Cabazitaxel (25 mg/m2 every 3 weeks) was approved for this indication in 2010.

View Article @ voice.ons.org

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles